ZMS-7506 / Simcere - LARVOL DELTA

A novel investigation of the cyclin A/B inhibitor ZMS-7506 demonstrates robust anti-tumor efficacy both in vitro and in vivo (AACR 2026) - "Moreover, ZMS-7506 exhibited robust antitumor efficacy as a monotherapy in the SCLC NCI-H69 xenograft mouse model. In summary, ZMS-7506 is a highly selective oral Cyclin A/B inhibitor with promising therapeutic potential as a monotherapy for cancers characterized by elevated E2F activity."

Preclinical • Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • CCNA2 • CDK2 • KNL1 • RB1 • TP53